In vivo and in vitro characterization of poly(styrene‐b‐isobutylene‐b‐styrene) copolymer stent coatings for biostability, vascular compatibility and mechanical integrity
Source abstract
Abstract
Abstract The TAXUS® Express 2™Paclitaxel Eluting Coronary Stent System employs a coating consisting of the thermoplastic elastomer, poly(styrene‐b‐isobutylene‐b‐styrene; SIBS), selected for its drug‐eluting characteristics, vascular compatibility, mechanical properties, and biostability. This study was conducted to evaluate the impact of different SIBS (17−51 mole % styrene) compositions on mechanical properties, chemical stability, and vascular compatibility. Mechanical property (stress−strain measurements) and stability studies were conducted on polymer films with five different styrene contents (17, 24, 32, 39, and 51 mole %). The ultimate tensile strength did not change significantly with composition, but the elongation at break decreased with increased styrene content. A pulsatile fatigue test further confirmed the mechanical stability of SIBS up to 39 mole % styrene. The vascular compatibility of five different SIBS compositions was assessed using SIBS‐only coated stents, in the coronary and carotid arteries in a porcine model study. The stability of the vessel wall, rate/degree of endothelialization, inflammation, and thrombus at timepoints from 30 to 180 days were evaluated. The results confirm vascular compatibility over the range of 17−51 mole % styrene. © 2009 Wiley Periodicals, Inc. J Biomed Mater Res, 2010
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Coronary Interventions and Diagnostics · Cardiac Valve Diseases and Treatments · Cardiac and Coronary Surgery Techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (22)
Show source-provided references
1. 10.1056/NEJMoa03244110.1056/NEJMoa032441 ↗
2. 10.1161/01.CIR.0000038982.49640.7010.1161/01.CIR.0000038982.49640.70 ↗
3. TAXUS® Express2® Paclitaxel‐eluting coronary stent system directions for use 90328768–01 Boston Scientific Corporation.
4. Cypher Sirolimus‐eluting Coronary Stent OTW and RX Instuctions for Use (Rev 9) 10056733‐8 Cordis: a Johnson and Johnson Company.
5. 10.1161/01.CIR.0000127129.94129.6F10.1161/01.CIR.0000127129.94129.6F ↗
6. ShanleyJF EiglerNL. Expandable medical device for delivery of beneficial agent U.S. Patent Application 20 040 254 635 December 2004.
7. 10.4161/cc.3.8.98610.4161/cc.3.8.986 ↗
8. 10.1016/j.addr.2006.01.02310.1016/j.addr.2006.01.023 ↗
9. 10.1002/jbm.a.3018810.1002/jbm.a.30188 ↗
10. 10.1016/0032-3861(96)89388-810.1016/0032-3861(96)89388-8 ↗
11. 10.1016/B978-012582460-6/50002-510.1016/B978-012582460-6/50002-5 ↗
12. Williams DF · 1990
13. PinchukL. Biostable elastomeric polymers having quaternary carbons U.S. Patent 5 741 331 April 1998.
14. Pinchuk L · 2000 · 1452
15. 10.1021/bm034513k10.1021/bm034513k ↗
16. 10.1097/00019501-200409000-0000310.1097/00019501-200409000-00003 ↗
17. 10.1161/01.CIR.94.7.169010.1161/01.CIR.94.7.1690 ↗
18. 10.1161/01.CIR.0000033485.20594.6F10.1161/01.CIR.0000033485.20594.6F ↗
19. 10.1080/1060132920805218910.1080/10601329208052189 ↗
20. 10.1016/j.cardiores.2007.07.00410.1016/j.cardiores.2007.07.004 ↗
21. 10.1080/1060132940935011910.1080/10601329409350119 ↗
22. In vitro and in vivo evaluation of the safety and stability of the TAXUS® paclitaxel‐eluting coronary stent